Tag Archive for: breast cancer

CEO Jack Bailey said G1 will evaluate other uses for trilaciclib and will pursue partners to expand its use globally.

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu significantly improved progression-free survival in metastatic breast patients with low and ultralow HER2 expression levels who had received at least one line of systemic treatment.

BioNTech and its partner Duality Biologics said they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca, and Daiichi Sankyo.

The company announced that it signed an exclusive license and collaboration agreement with SystImmune to develop the biotech’s investigational bi-specific antibody-drug conjugate BL-B01D1 as a treatment for solid tumors.

At this year’s European Society for Medical Oncology, excitement topped 2022 levels on NSCLC and breast cancer innovation.

The company’s blockbuster cancer asset Keytruda brought in more than $6.3 billion in the third quarter, a 17% increase from the same period last year, while bolstering its antibody-drug conjugate portfolio.

The companies presented data from two pivotal studies of Dato-DXd, focusing on safety concerns and survival data for the investigational antibody-drug conjugate candidate in lung and breast cancer.

MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of MediLink’s ADC assets, and BioNTech will provide MediLink with an upfront payment totaling of $70 million and additional development, regulatory and commercial milestone payments potentially totaling over $1 billion.

AstraZeneca said on its experimental precision drug had slowed the progression of a common type of breast cancer in a late-stage trial, a boost for the company after its shares fell in July on results from a separate trial of the same drug for lung cancer.

Let’s think of this Barbie phenomenon as a catalyst to put women’s health and well-being at the forefront. How can we, as pharma marketers, keep the momentum going?